Selective Glucosylceramide Synthase Inhibition with Lysosomal Enhancement
🧪 Overview
Dual targeting approach using substrate reduction therapy (eliglustat) combined with TFEB activators to reduce GlcCer accumulation while enhancing lysosomal clearance
Debate provenance: derived from debate `sess_sda-2026-04-01-002` on question: How to break the GBA-alpha-synuclein bidirectional loop for Parkinson's Disease therapy?. Consensus signal: domain_expert, skeptic, synthesizer, theorist discussed the mechanism terms Enhancement, Glucosylceramide, Inhibition, Lysosomal, Selective, Synthase, TFEB, UGCG. Novelty signal: skeptic-discussed-with-qualified-concession.
🧬 Mechanism
Auto-built from this analysis's top knowledge-graph edges.
graph TD
alpha_synuclein["alpha_synuclein"] -.->|inhibits| glucocerebrosidase["glucocerebrosidase"]
glucocerebrosidase_1["glucocerebrosidase"] -->|regulates| Glucosylceramide["Glucosylceramide"]
Glucosylceramide_2["Glucosylceramide"] -->|enhances| alpha_synuclein_3["alpha_synuclein"]
eliglustat["eliglustat"] -.->|inhibits| Glucosylceramide_4["Glucosylceramide"]
alpha_synuclein_5["alpha_synuclein"] -->|associated with| Parkinson_s_disease["Parkinson's_disease"]
Glucosylceramide_6["Glucosylceramide"] -->|enhances| Alpha_Synuclein_Oligomers["Alpha-Synuclein Oligomers"]
GBA_dysfunction["GBA dysfunction"] -->|causes| Lysosomal_Impairment["Lysosomal Impairment"]
glucocerebrosidase_7["glucocerebrosidase"] -->|regulates| lysosomal_degradation["lysosomal degradation"]
alpha_synuclein_8["alpha-synuclein"] -.->|inhibits| glucocerebrosidase_9["glucocerebrosidase"]
glucosylceramide["glucosylceramide"] -->|stabilizes| alpha_synuclein_oligomers["alpha-synuclein oligomers"]
glucosylceramide_synthase["glucosylceramide synthase"] -->|causes| glucosylceramide_10["glucosylceramide"]
Eliglustat["Eliglustat"] -->|prevents| glucosylceramide_accumula["glucosylceramide accumulation"]
style alpha_synuclein fill:#4fc3f7,stroke:#333,color:#000
style glucocerebrosidase fill:#4fc3f7,stroke:#333,color:#000
style glucocerebrosidase_1 fill:#4fc3f7,stroke:#333,color:#000
style Glucosylceramide fill:#4fc3f7,stroke:#333,color:#000
style Glucosylceramide_2 fill:#4fc3f7,stroke:#333,color:#000
style alpha_synuclein_3 fill:#4fc3f7,stroke:#333,color:#000
style eliglustat fill:#4fc3f7,stroke:#333,color:#000
style Glucosylceramide_4 fill:#4fc3f7,stroke:#333,color:#000
style alpha_synuclein_5 fill:#4fc3f7,stroke:#333,color:#000
style Parkinson_s_disease fill:#ef5350,stroke:#333,color:#000
style Glucosylceramide_6 fill:#4fc3f7,stroke:#333,color:#000
style Alpha_Synuclein_Oligomers fill:#4fc3f7,stroke:#333,color:#000
style GBA_dysfunction fill:#4fc3f7,stroke:#333,color:#000
style Lysosomal_Impairment fill:#4fc3f7,stroke:#333,color:#000
style glucocerebrosidase_7 fill:#4fc3f7,stroke:#333,color:#000
style lysosomal_degradation fill:#81c784,stroke:#333,color:#000
style alpha_synuclein_8 fill:#4fc3f7,stroke:#333,color:#000
style glucocerebrosidase_9 fill:#4fc3f7,stroke:#333,color:#000
style glucosylceramide fill:#4fc3f7,stroke:#333,color:#000
style alpha_synuclein_oligomers fill:#4fc3f7,stroke:#333,color:#000
style glucosylceramide_synthase fill:#4fc3f7,stroke:#333,color:#000
style glucosylceramide_10 fill:#4fc3f7,stroke:#333,color:#000
style Eliglustat fill:#4fc3f7,stroke:#333,color:#000
style glucosylceramide_accumula fill:#4fc3f7,stroke:#333,color:#000⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — UGCG
No curated PDB or AlphaFold mapping for UGCG yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for UGCG + TFEB.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_round_mining
| source | v1_phase_c_backfill |
| origin_type | debate_round_mining |
| _schema_version | 1 |